GlaxoSmithKline Q2 Profit Down; Says Confident In FY21 View; Confirms FY22 Forecast

Drug major GlaxoSmithKline plc (GSK,GSK.L) reported Wednesday that its second-quarter profit before taxation fell 44 percent to 1.47 billion pounds from last year's 2.64 billion pounds.

Earnings per share were 27.9 pence, down 45.5 pence last year. Adjusted earnings per share were 28.1 pence, compared to 19.2 pence last year.

Turnover grew 6 percent 8.09 billion pounds from 7.62 billion pounds last year. Revenues increased 15 percent at constant currency rates.

Pharmaceuticals revenues grew 3 percent, and vaccines revenues climbed 39 percent, while Consumer Healthcare revenues fell 4 percent.

Looking ahead, the company said it is confident in delivering fiscal 2021 earnings per share guidance and reconfirmed 2022 outlook.

For the year 2021, the companies to expect a decline of mid to high-single digit percent adjusted earnings per share at CER, excluding any contribution from COVID-19 solutions. The company said it is likely to deliver full-year adjusted earnings per share towards the better end of guidance range.

For 2022, the company expects meaningful improvements in revenues and margins.

Further, the company declared 19 pence per share dividend for the second quarter. For 2021, the company continues to expect 80 pence per share.

GSK expects to deliver step-change in sales, operating profit growth and performance from 2022, driven by high quality Vaccines and Specialty Medicines portfolio and late-stage pipeline

The company said the proposed demerger to create new world-leading Consumer Healthcare company confirmed for mid-2022.

In London, GSK shares were trading 1,391.80 pence, down 0.53 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT